Wave Life Sciences Ltd.

WVESEC EDGAR

Pharmaceutical Preparations(U0)CIK: 1631574

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$113.3M	$3.6M	$3.6M	$41.0M	$20.1M
Research and Development Expense	$130.0M	$115.9M	$115.9M	$121.9M	$130.9M
Operating Expenses	$181.3M	$166.4M	$166.4M	$168.0M	$173.5M
Operating Income (Loss)	-$68.0M	-$162.7M	-$162.7M	-$127.0M	-$153.4M
Nonoperating Income (Expense)	$9.8M	$1.6M	$1.6M	$4.6M	$2.6M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$58.2M	-$161.1M	-$161.1M	-$122.4M	-$150.8M
Income Tax Expense (Benefit)	-$677.0K	$681.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$352.2M	$274.9M	$146.4M	$207.0M	$279.2M
Assets, Current	$320.4M	$235.4M	$98.5M	$162.6M	$230.0M
Cash and Cash Equivalents, at Carrying Value	$302.1M	$200.4M	$88.5M	$150.6M	$184.5M
Accounts Receivable, after Allowance for Credit Loss, Current	$1.4M	$21.1M	$21.1M	—	$30.0M
Liabilities	$134.8M	$227.4M	$183.6M	$166.6M	$188.6M
Liabilities, Current	$111.0M	$186.4M	$71.5M	$64.2M	$121.0M
Accounts Payable, Current	$16.3M	$12.8M	$16.9M	$7.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$19.4M	-$127.8M	-$127.8M	-$89.0M	-$116.0M
Net Cash Provided by (Used in) Investing Activities	-$1.1M	-$1.3M	-$1.3M	-$560.0K	-$1.3M
Net Cash Provided by (Used in) Financing Activities	$132.5M	$67.2M	$67.2M	$55.8M	$154.5M
Payments to Acquire Property, Plant, and Equipment	$1.1M	$1.4M	$1.4M	$560.0K	$1.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)